Bionovate Technologies Net Income Over Time
| BIIO Stock | USD 0.0001 0.00 0.000003% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bionovate Technologies Performance and Bionovate Technologies Correlation. Bionovate | Build AI portfolio with Bionovate Stock |
Will Health Care Equipment & Supplies sector continue expanding? Could Bionovate diversify its offerings? Factors like these will boost the valuation of Bionovate Technologies. Projected growth potential of Bionovate fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bionovate Technologies data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Bionovate Technologies's market price often diverges from its book value, the accounting figure shown on Bionovate's balance sheet. Smart investors calculate Bionovate Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Bionovate Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bionovate Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bionovate Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bionovate Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Bionovate Technologies and related stocks such as Allurion Technologies, Aethlon Medical, and Co Diagnostics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALUR | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (12.4 M) | (37.7 M) | (80.6 M) | (26.1 M) | (23.5 M) | (24.7 M) |
| AEMD | (1.5 K) | (8.1 M) | (4.9 M) | (13.4 M) | (6.8 M) | (4.9 M) | (7.3 M) | (5.7 M) | (6.2 M) | (6.4 M) | (7.8 M) | (10.4 M) | (12 M) | (12.2 M) | (13.4 M) | (12 M) | (11.4 M) |
| CODX | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (2 M) | (1.9 M) | (7 M) | (6.3 M) | (6.2 M) | 42.5 M | 36.7 M | (14.2 M) | (35.3 M) | (37.6 M) | (33.9 M) | (32.2 M) |
| VVOS | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (10.8 M) | (12.1 M) | (20.3 M) | (23.8 M) | (13.6 M) | (11.1 M) | (10 M) | (10.5 M) |
| EKSO | (15 M) | (15 M) | (15 M) | (12.3 K) | (33.8 M) | (19.6 M) | (23.5 M) | (29.1 M) | (27 M) | (12.1 M) | (15.8 M) | (9.8 M) | (15.1 M) | (15.2 M) | (11.3 M) | (13 M) | (13.7 M) |
| ADGM | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (19.9 M) | (23.7 M) | (38.1 M) | (53.8 M) | (48.4 M) | (46 M) |
| AYTU | (49 K) | (59.7 K) | (57.3 K) | (5.6 M) | (7.7 M) | (28.2 M) | (22.5 M) | (10.2 M) | (47.2 M) | (13.6 M) | (58.3 M) | (108.8 M) | (17.1 M) | (15.8 M) | (13.6 M) | (12.2 M) | (12.8 M) |
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| PRPH | (700 K) | (2.7 M) | (1.1 M) | 405 K | (7.8 M) | (3.6 M) | (2.9 M) | 41.8 M | (1.7 M) | (3.1 M) | (2.1 M) | 6.3 M | 18.5 M | (16.8 M) | (53.4 M) | (48 M) | (45.6 M) |
Bionovate Technologies and related stocks such as Allurion Technologies, Aethlon Medical, and Co Diagnostics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Bionovate Technologies financial statement analysis. It represents the amount of money remaining after all of Bionovate Technologies Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Bionovate Technologies Corp | BIIO |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | Gewerbestrasse 10, Cham, |
| Exchange | OTCCE Exchange |
USD 1.0E-4
Check out Bionovate Technologies Performance and Bionovate Technologies Correlation. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Bionovate Technologies technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.